And a second webinar this week presented by abcam:


Thursday, June 16, 2016
3pm-4pm CET / 2pm-3pm GMT / 9am-10am EST

Webinar Overview:

Drug‑induced cardiac injury (DICI) detection remains a major safety issue in drug development. While circulating microRNAs (miRs) have emerged as promising translational biomarkers, novel early detection biomarkers of cardiotoxicity are needed to evaluate toxicity in a time-dependent manner.

This webinar will review: [click to continue…]


PHILADELPHIA and REHOVOT, Israel, June 28, 2011 /PRNewswire/ — Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces it has entered into a collaboration with the University of California,  Davis (“UC Davis” or the “University”) to develop and validate a microRNA profile for muscle-invasive bladder cancer (MI-BC) that is predictive of patient response to neoadjuvant chemotherapy.  The collaboration allows for UC Davis researchers to continue using Rosetta’s platforms and microRNAs to further discover new biomarkers and validate their results.

Researchers have initiated collaborations by studying 55 MI-BC patients treated at UC Davis Cancer Center with neoadjuvant chemotherapy. The primary goal of this study is to develop and validate a microRNA profile of MI-BC that is predictive of patient response to neoadjuvant chemotherapy.  A secondary goal of the study is to understand the mechanism by which differentially expressed microRNAs mediate chemosensitivity.

Approximately 30 percent of bladder cancer patients present with or will develop MI-BC, which has a five-year survival rate of approximately 50 percent.  Evidence-based medicine has clearly demonstrated the survival benefit of [click to continue…]


microRNAs as Biomarkers in Plasma

by Chris on October 20, 2010

in Technical Article

MicroRNAs (miRNAs) are small non-coding RNAs found in eukaryotic organisms that regulate gene expression. Dismissed as “junk” until about a decade ago, it is now widely accepted that they play an important functional role in a wide array of cellular processes.

MiRNAs regulate gene expression by targeting individual or multiple messenger RNAs (mRNAs). Perfect or partial base pairing with the target mRNA promotes cleavage of the RNA in plants and inhibition of protein translation in animals. Many studies have demonstrated that dysregulation of these miRNAs is associated with various diseases suggesting there is potential for use of miRNAs in diagnosis and treatment.

Much of the study of miRNA and disease has focused on cancer and neurological disorders. Not surprising since cancer is the leading cause of death worldwide in 2010 and it is estimated that neurological disorders may affect as many as a billion people. There are urgent needs for early diagnosis and treatment in both areas.

Several miRNAs have been linked with various types of cancer due to their regulatory role in cellular development, including: differentiation, proliferation, and apoptosis. Neural miRNAs are known to be involved at various stages of synaptic development, including: dendritogenesis, synapse formation and synapse maturation. Since miRNAs exhibit specific expression profiles in tissues and tumor cells it makes sense that they could serve as biomarkers for these and other diseases.  (read more… )

Incoming search terms for this article:


DALLAS, Sept. 17 /PRNewswire-USNewswire/ — For the first time, scientists have found that blood levels of some ribonucleic acids (microRNAs) are different among people with type 2 diabetes and those who subsequently develop the disease compared to healthy controls, according to research reported in Circulation Research: Journal of the American Heart Association1.

Changes in five specific microRNAs correctly identified most cases of diabetes and even some patients who later developed diabetes, while normal levels of these microRNAs classified 92 percent of healthy controls.

Of the microRNAs studied, microRNA 126, which promotes blood vessel growth, was among the most predictive of diabetes.

Read the entire press release

  1. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. (2010) Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes. Circ Res 107(6), 810-17. [abstract]

Incoming search terms for this article:



3/22/10 – 3/24/10  Boston, MA


microRNA in Cancer
microRNA in Biomarker and Diagnostic Development
microRNA in Therapeutic Development
microRNA in Human Development and Disease
microRNA Pathways and Mechanisms